Abera Bioscience
6,40 SEK
-2,29 %
Mindre end 1K følgere
ABERA
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
-2,29 %
+10,34 %
-5,88 %
-5,88 %
-2,29 %
+9,97 %
+16,36 %
-39,05 %
-42,08 %
Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.
Læs mereMarkedsværdi
131,19 mio. SEK
Aktieomsætning
53,71 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
Omsætning
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
12.5
2026
Delårsrapport Q1'26
10.6
2026
Generalforsamling '26
20.8
2026
Delårsrapport Q2'26